Clinical Trials
133 trialsA Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
Centre Antoine Lacassagne
ARC-25
Arcus Biosciences, Inc.
OTT15-04
Ottawa Hospital Research Institute
APHINITY
Hoffmann-La Roche
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
ImmunityBio, Inc.
TNBC
ImmunityBio, Inc.
SAFIR02_Breast
UNICANCER
PANTHER
Karolinska University Hospital
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
ImmunityBio, Inc.
COC-IDCB
Shanghai Jiao Tong University School of Medicine
TRAIN-2
The Netherlands Cancer Institute
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
TavIx
UNICANCER
NASBP-B-09
Paradyne Networks A Foundation
ANZAC
Sheffield Teaching Hospitals NHS Foundation Trust
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Austrian Breast & Colorectal Cancer Study Group
Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment
Spanish Breast Cancer Research Group
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
Spanish Breast Cancer Research Group
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
Spanish Breast Cancer Research Group
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Hoffmann-La Roche
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
NSABP Foundation Inc
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Hoffmann-La Roche
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NeoPAL
UNICANCER
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
M.D. Anderson Cancer Center
BERENICE
Hoffmann-La Roche
INDUCT
GlaxoSmithKline
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Austrian Breast & Colorectal Cancer Study Group
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
Canadian Cancer Trials Group
BETH
NSABP Foundation Inc
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Louisiana State University Health Sciences Center Shreveport
Primary Breast Cancer Occurring Concomitant With Pregnancy
M.D. Anderson Cancer Center
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
Fudan University
Tamoxifen in Treating Women With High-Risk Breast Cancer
Canadian Cancer Trials Group
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Yale University
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
RenJi Hospital
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
Fudan University
Beverly1
UNICANCER